フォルテ・バイオサイエンシズ
Forte Biosciences, Inc.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.97 | $0 | $19M |
| 2026 Q1 | -1.24 | $0 | -$19M |
| 2025 Q4 | -1.39 | $0 | -$16M |
| 2025 Q3 | -0.99 | $0 | -$14M |
| 2025 Q2 | -0.96 | $0 | -$10M |
| 2025 Q1 | -1.37 | $0 | -$10M |
| 2024 Q4 |
| -1.12 |
| $0 |
| -$10M |
| 2024 Q3 | -4.54 | $0 | -$8M |